

The research to establish the drug for white skin through analysis of melanin production

Masashi Kato

Department of Environmental and Preventive Medicine, Research Institute of Life and Health Sciences, Chubu University

Malignant melanoma is one of the most aggressive tumors. Incidence of melanomas is increasing by upregulation of ultraviolet irradiation. Therefore, it is necessary to establish a new drug for preventing against and curing melanoma through the clarification of its mechanism. We established the RET-transgenic mouse line (304/B6), in which spontaneously develops benign melanocytic tumor(s) without exception. About 70% of the benign tumors will be changed to malignant melanomas. We investigated the role of c-Kit in the hereditary melanoma developed in the RET-transgenic mice (line 304/B6). In W^V/W^V -RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of melanoma was strongly suppressed. Whereas 31 of the 44 original RET-transgenic mice died of rapidly growing melanoma within 12 months after birth, only 8 of the 44 W^V/W^V -RET-transgenic mice developed slowly-growing melanocytic tumors with a greatly prolonged mean tumor-free period, two of which died of melanoma at a late stage. Even $W^V/+$ -RET-transgenic mice had a clearly prolonged tumor-free period and a definitely reduced frequency (6/61) of tumor death within 12 months after birth. Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of melanomas in these mice with only minor effects in melanin production. More importantly, a single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of melanoma, greatly prolonging the tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice had died from tumors at 12 months of age. The c-Kit function needed for melanin production was also suppressed for an unusual long time in ACK2-treated RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule to prevent against melanoma. In the next step, we should clarify whether c-Kit can be a target of therapy for the developed melanoma or not.